An Implementer’s Guide to the Tenofovir Disoproxil Fumarate-Lamivudine Dolutegravir (TLD) Transition.
An Implementer’s Guide to the Tenofovir Disoproxil Fumarate-Lamivudine Dolutegravir (TLD) Transition
Objective: This best practice symposium provided a forum for National Department of Health, partners and local stakeholders to interact with counterparts from regional countries (Botswana, Malawi, Zambia and Malawi) to discuss experiences and showcase strategies and plans that will enable the roll out of Dolutegravir and to discuss strategies for monitoring outcomes in patients exposed to TLD.
- Agenda (PDF 212KB)
- Birth Surveillance Uganda: Dr Daniel Mumpe (PDF 454KB)
- Dolutegravir based regimens in first and second line HIV Treatment: Dr Nathan Ford, WHO (PDF 2.5MB)
- Dolutegravir Civil Society Perspective: Mr Patrick Mdletshe, TAC (PDF 338KB)
- Dolutegravir in pregnancy SA experience: Dr Lee Failea, Wits RHI (PDF 1.9MB)
- Experiences with a Pregnancy Registry South Africa: Dr Mukesh Dheda, National Department of Health (PDF 258KB)
- Malawi TLD Roll out: Dr Brown Chiwandira, Malawi Ministry of Health (PDF 253KB)
- National Pregnancy Exposure Registry: Dr Ushma Mehta, University of Cape Town (PDF, 636KB)
- Preliminary findings TLD: Dr Elvis Temfack, MSF, Malawi (PDF 252KB)
- Roll out and Pharmacovigilance of Dolutegravir in the Zambia: Prof Lloyd Mulenga, Zambia Ministry of Health (PDF 1.9KB)
- Safety surveillance for dolutegravir: Prof Andrew Boulle, University of Cape Town (PDF 580KB)